Background: Mitral valve repair is preferred in patients undergoing surgical treatment for infective endocarditis (IE) of the native mitral valve, however, radical resection of infected tissue and patch-plasty might potentially lead to low or non-durable repair. We aimed to compare a limited-resection and non-patch technique with the classic radical-resection technique. Methods: Eligible candidates were patients with definitive IE of the native mitral valve undergoing surgery between January 2013 and December 2018. Patients were classified according to the surgical strategy into two groups: limited- versus radical-resection strategy. Propensity score matching was used. Endpoints were repair rate, all-cause mortality (30-day and 2-year), re-endocarditis and reoperation at q-year follow-up. Results: After propensity score matching, 90 patients were included. Follow-up was 100% complete. Mitral valve repair rate was 84% in the limited-resection versus 18% in the radical-resection strategy, p < 0.001. The 30-day and 2-year mortality were 20% versus 13% (p = 0.396) and 33% versus 27% (p = 0.490) in the limited-resection versus radical-resection strategy, respectively. The incidence of re-endocarditis during the 2-year follow-up was 4% in the limited-resection strategy versus 9% in the radical-resection strategy, p = 0.677. Three patients in the limited-resection strategy underwent reoperation of the mitral valve, while there were none in the radical-resection strategy (p = 0.242). Conclusions: Although mortality in patients with IE of the native mitral valve remains high, the limited-resection and non-patch surgical strategy is associated with a significantly higher repair rates with comparable 30-day and mid-term mortality, risk of re-endocarditis and re-operation compared to the radical-resection strategy.
Background: Aortic valve infective endocarditis (IE) complicated by an aortic root abscess is a challenging problem that leads to increased morbidity and mortality. Aortic root repair or replacement are two potential treatment options. We aimed to compare patients undergoing aortic root repair or replacement with short- and mid-term outcomes. Methods: Consecutive patients with active aortic valve IE complicated by aortic root abscess undergoing cardiac surgery from January 2012 to January 2022 were included. Patients receiving aortic root repair were compared to patients undergoing aortic root replacement. Endpoints included overall mortality, incidence of recurrent IE and re-intervention during a two-year follow-up period. Inverse propensity weighting was employed to adjust for confounders. Results: Seventy-three patients with aortic valve IE with root abscess underwent surgical therapy. Fifty-six patients received aortic root repair and seventeen patients underwent aortic root replacement. Patients undergoing root replacement had significantly higher surgical risk (EuroSCORE II: 9 versus 19, p = 0.02) and extended disease (circumferential annular abscess: 9% versus 41%, p < 0.01). Inverse propensity weighted analysis revealed no relationship between surgical strategy and outcome. Weighted regression analysis revealed EuroSCORE II and disease extension as significant predictors of 30-day and 2-year mortality. Conclusions: In patients with aortic valve IE with root abscess, root repair is mostly performed in lower-risk patients with limited disease extension. Short- and mid-term mortality, recurrent endocarditis and reintervention were comparable between surgical strategies during follow-up. Surgical risk and disease extension, rather than surgical strategy, seem to be significant predictors of short- and mid-term mortality.
Objectives: Infective endocarditis of the aortic valve complicated by annular abscess is a challenging problem and often requires patch reconstruction after surgical debridement of the abscess cavity. Filling the remaining cavity with antibiotics is advocated to prevent recurrent endocarditis. This study aimed at evaluating the role of local antibiotics in patients with aortic valve infective endocarditis complicated by annular abscess. Methods: Between January 2012 and December 2021, all consecutive patients with aortic valve infective endocarditis complicated by annular abscess undergoing cardiac surgery and annular patch reconstruction were included. Patients receiving local antibiotics were compared with patients without local antibiotics. The primary endpoints were the incidence of recurrent endocarditis, re-operation, and mortality during two-year follow-up. Results: A total of 41 patients with aortic valve infective endocarditis complicated by annular abscess underwent surgical patch reconstruction after radical debridement. In total, 20 patients received local antibiotics in the abscess cavity and 21 patients were treated without local antibiotics. The most common causative microorganisms were the staphylococci species and the most common location of the abscess was the non-coronary annulus. During two-year follow-up, one patient in each group developed recurrent endocarditis (p > 0.99) and both patients were reoperated (p > 0.99). Two-year mortality was 30% in the local antibiotic group and 24% in the control group (p = 0.65). Conclusions: Radical debridement and patch reconstruction of the aortic annulus in patients with aortic valve infective endocarditis complicated by annular abscess is an effective surgical strategy. Filling of the remaining abscess cavity with antibiotic seems not to affect the rate of recurrent endocarditis, reoperation, and mortality during two-year follow-up.
Background: The guidelines recommend mitral valve repair whenever possible in patients undergoing surgical treatment for active infective endocarditis of the native mitral valve. However, the impact of causative microorganisms in relation to treatment strategies, especially Staphylococcus aureus, has not been studied. In this study, we aimed to compare the outcomes of mitral valve repair versus replacement in patients with native mitral valve infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Methods: Consecutive patients with definitive active infective endocarditis of the native mitral valve caused by methicillin-susceptible Staphylococcus aureus undergoing cardiac surgery between 2012 and 2022 were selected. Patients were classified according to the treatment received in two groups: repair and replacement. Inverse propensity treatment weighting was employed to correct for confounders. The endpoints were all-cause mortality, incidence of recurrent endocarditis, reoperation rate, and event-free survival at two-year follow-up. Results: Among 170 operated-upon patients with active infective endocarditis of the native mitral valve, 44 cases were caused by methicillin-susceptible Staphylococcus aureus. A total of 23 patients underwent mitral valve repair and 21 patients received mitral valve replacement. Weighted 30-day mortality in the repair group was 43%, versus 27% in the replacement group (p = 0.15). Two-year mortality increased to 57% in the repair group and 32% in the replacement group (p = 0.02). Three patients developed recurrent endocarditis in the repair group, while no recurrent endocarditis occurred in the replacement group. Three patients in the repair group required reoperation due to recurrence and one patient in the replacement group underwent re-operation due to paravalvular leakage. Weighted two-year event-free survival was 29% in the repair group and 59% in the replacement group (p < 0.01). Conclusions: Mortality in patients with mitral valve infective endocarditis caused by Staphylococcus aureus is extremely high, especially in patients undergoing mitral valve repair. The risk of recurrent endocarditis and mid-term mortality seems to be higher in mitral valve repair, resulting in poor event-free survival during two-year follow-up. However, the sample size was likely insufficient for drawing definitive conclusions.
Background: Vasoplegia after heart failure surgery has been associated with increased morbidity and mortality. The aim of this study was to evaluate the incidence and impact of postoperative vasoplegia in patients undergoing durable continuous flow left ventricular assist device implantation (cfLVAD). Methods: All patients who underwent cfLVAD implantation were included in this analysis. Vasoplegia was defined as the need for norepinephrine ≥0.2 μg/kgBW/min and/or any vasopressin dose for ≥12 h starting within 72 h postoperatively without bleeding/pericardial tamponade requiring surgical revision. Endpoints included the incidence of vasoplegia and 30- and 90-day mortality. Cox proportional hazard model was used to assess the association between vasoplegia and mortality. Multivariate logistic regression analysis was performed to identify predictors of vasoplegia. Results: Between 08/2010 and 12/2023, 307 consecutive patients underwent durable cfLVAD implantation. Mean age was 58 ± 11 years. Of the patients, 94% were operated with cardiopulmonary bypass and in 71% intraoperative hemoadsorption was applied. The incidence of vasoplegia was 23%. Vasoplegia was significantly associated with increased short-term mortality compared to non-vasoplegic patients (HR: CI: p < 0.001). Multivariate regression analysis identified preoperative invasive ventilation and preoperative vasopressor support as strong risk factors for postoperative vasoplegia, while intraoperative hemoadsorption reduced this risk. Conclusion: Vasoplegia after durable cfLVAD implantation is a common and serious complication associated with increased short-term mortality. Preoperative mechanical ventilation and vasopressor support are risk factors for developing postoperative vasoplegia. Intraoperative hemoadsorption appears to reduce the risk of vasoplegia after durable cfLVAD implantation.
Background: Current guidelines recommend mitral valve (MV) repair over replacement for active native valve endocarditis. However, traditional techniques involving radical debridement and prosthetic patch reconstruction may limit repair feasibility and long-term durability. This study evaluates the long-term clinical outcomes of an alternative approach utilizing a limited resection and non-patch technique in patients presenting with active native MV endocarditis. Methods: Consecutive patients with definite active native MV endocarditis who underwent surgical treatment between January 2016 and December 2021 were retrospectively reviewed. From this cohort, all patients managed with MV repair using a limited resection strategy without patch plasty were selected and compared to patients undergoing MV replacement after radical resection. The prespecified primary endpoints were overall mortality, the incidence of recurrent endocarditis, and the rate of reoperation during five-year follow-up. The Cox proportional hazards model was used to identify predictors of overall mortality and adverse events (composite of death, recurrence, and/or reoperation). Results: Out of 128 patients with active native MV endocarditis, 75 patients successfully underwent MV repair via the limited resection and non-patch technique and 53 patients received MV replacement. Five-year mortality rates were 43% in the repair group and 52% in the replacement group, p = 0.31. Six patients developed recurrent endocarditis in the repair group, while one patient developed it in the replacement group. Reoperation was necessary in five cases in the repair group, while one patient in the replacement group required reoperation due to paravalvular leakage. Surgical strategy was not associated with mortality or adverse events. Staphylococcal endocarditis was a strong predictor of overall mortality (HR: 2.2 (1.3–3.7)) and adverse events (HR: 2.2 (1.0–4.9)). Conclusions: A limited resection approach for active native MV endocarditis appears to be a feasible surgical strategy to enhance valve reparability, particularly in non-staphylococcal cases. Conversely, staphylococcal endocarditis remains a potent independent risk factor associated with increased mortality and adverse events.